Topline data were announced from a phase 2/3 trial evaluating tovecimig plus paclitaxel in patients with advanced biliary tract cancer.

Osamu Morishita, head of the sustainability promotion department at Mizuho Securities, reflects on the outlook for sustainability in the Japanese market for 2025.